10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
MERCK & CO., INC. | |||
Ticker: MRK Fiscal Year: 2016 | |||
Consolidated Statement of Cash Flows | |||
Period Ending Dec 31, 2016 10-K (Filed: Feb 28, 2017) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | |
| Cash Flows from Operating Activities | |||
| Net income | $ 3,941 | 4,459 | 11,934 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation and amortization | 5,441 | 6,375 | 6,691 |
| Intangible asset impairment charges | 3,948 | 162 | 1,222 |
| Charge related to the settlement of worldwide Keytruda patent litigation | 625 | 0 | 0 |
| Foreign currency devaluation related to Venezuela | 0 | 876 | 0 |
| Net charge related to the settlement of Vioxx shareholder class action litigation | 0 | 680 | 0 |
| Gain on divestiture of Merck Consumer Care business | 0 | 0 | (11,209) |
| Gain on AstraZeneca option exercise | 0 | 0 | (741) |
| Loss on extinguishment of debt | 0 | 0 | 628 |
| Equity income from affiliates | (86) | (205) | (257) |
| Dividends and distributions from equity method affiliates | 16 | 50 | 185 |
| Deferred income taxes | (1,521) | (764) | (2,600) |
| Share-based compensation | 300 | 299 | 278 |
| Other | 313 | 874 | 34 |
| Net changes in assets and liabilities: | |||
| Accounts receivable | (619) | (480) | (554) |
| Inventories | 206 | 805 | 79 |
| Trade accounts payable | 278 | (37) | 593 |
| Accrued and other current liabilities | (2,018) | (8) | 1,635 |
| Income taxes payable | 124 | (266) | (21) |
| Noncurrent liabilities | (809) | (277) | 190 |
| Other | 237 | (5) | (98) |
| Net Cash Provided by Operating Activities | 10,376 | 12,538 | 7,989 |
| Cash Flows from Investing Activities | |||
| Capital expenditures | (1,614) | (1,283) | (1,317) |
| Purchases of securities and other investments | (15,651) | (16,681) | (24,944) |
| Proceeds from sales of securities and other investments | 14,353 | 20,413 | 15,114 |
| Divestiture of Merck Consumer Care business, net of cash divested | 0 | 0 | 13,951 |
| Dispositions of other businesses, net of cash divested | 0 | 316 | 1,169 |
| Proceeds from AstraZeneca option exercise | 0 | 0 | 419 |
| Acquisition of Cubist Pharmaceuticals, Inc., net of cash acquired | 0 | (7,598) | 0 |
| Acquisition of Idenix Pharmaceuticals, Inc., net of cash acquired | 0 | 0 | (3,700) |
| Acquisitions of other businesses, net of cash acquired | (780) | (146) | (181) |
| Acquisition of Bayer AG collaboration rights | 0 | 0 | (1,000) |
| Cash inflows from net investment hedges | 29 | 139 | 195 |
| Other | 453 | 82 | (80) |
| Net Cash Used in Investing Activities | (3,210) | (4,758) | (374) |
| Cash Flows from Financing Activities | |||
| Net change in short-term borrowings | 0 | (1,540) | (460) |
| Payments on debt | (2,386) | (2,906) | (6,617) |
| Proceeds from issuance of debt | 1,079 | 7,938 | 3,146 |
| Purchases of treasury stock | (3,434) | (4,186) | (7,703) |
| Dividends paid to stockholders | (5,124) | (5,117) | (5,170) |
| Other dividends paid | 0 | 0 | (77) |
| Proceeds from exercise of stock options | 939 | 485 | 1,560 |
| Other | (118) | (61) | 79 |
| Net Cash Used in Financing Activities | (9,044) | (5,387) | (15,242) |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | (131) | (1,310) | (553) |
| Net (Decrease) Increase in Cash and Cash Equivalents | (2,009) | 1,083 | (8,180) |
| Cash and Cash Equivalents at Beginning of Year | 8,524 | 7,441 | |
| Cash and Cash Equivalents at End of Year | 6,515 | 8,524 | 7,441 |
| External Links | |
| MERCK & CO., INC. (MRK) Fiscal Year 2016 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |